1. Home
  2. HITI vs MOLN Comparison

HITI vs MOLN Comparison

Compare HITI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo High Tide Inc.

HITI

High Tide Inc.

HOLD

Current Price

$2.85

Market Cap

257.8M

Sector

N/A

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$3.98

Market Cap

157.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
HITI
MOLN
Founded
2009
2004
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
257.8M
157.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HITI
MOLN
Price
$2.85
$3.98
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$6.13
$3.75
AVG Volume (30 Days)
551.9K
2.3K
Earning Date
01-28-2026
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$410,600,094.00
N/A
Revenue This Year
$14.07
N/A
Revenue Next Year
$29.67
$1,000.00
P/E Ratio
N/A
N/A
Revenue Growth
11.18
N/A
52 Week Low
$1.64
$3.36
52 Week High
$4.06
$5.91

Technical Indicators

Market Signals
Indicator
HITI
MOLN
Relative Strength Index (RSI) 53.97 44.51
Support Level $2.56 $4.13
Resistance Level $2.98 $4.57
Average True Range (ATR) 0.11 0.16
MACD 0.05 -0.03
Stochastic Oscillator 69.61 8.70

Price Performance

Historical Comparison
HITI
MOLN

About HITI High Tide Inc.

High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, Famous Brandz, and others. The company's reportable operating segments are; Bricks and mortar which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada followed by the United States of America, and other international markets.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: